Overview

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Status:
RECRUITING
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Junshi Bioscience Co., Ltd.
Treatments:
Bevacizumab
Capecitabine
Carboplatin
Cisplatin
Oxaliplatin
Paclitaxel
Pemetrexed